ATE337010T1 - Desinfizierende und solubilisierende steroidzusammensetzungen - Google Patents

Desinfizierende und solubilisierende steroidzusammensetzungen

Info

Publication number
ATE337010T1
ATE337010T1 AT02769298T AT02769298T ATE337010T1 AT E337010 T1 ATE337010 T1 AT E337010T1 AT 02769298 T AT02769298 T AT 02769298T AT 02769298 T AT02769298 T AT 02769298T AT E337010 T1 ATE337010 T1 AT E337010T1
Authority
AT
Austria
Prior art keywords
disinfecting
solubilizing
steroid compositions
prednisolone
cyclodextrin
Prior art date
Application number
AT02769298T
Other languages
English (en)
Inventor
Robert T Lyons
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE337010T1 publication Critical patent/ATE337010T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02769298T 2001-05-07 2002-04-29 Desinfizierende und solubilisierende steroidzusammensetzungen ATE337010T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28933701P 2001-05-07 2001-05-07

Publications (1)

Publication Number Publication Date
ATE337010T1 true ATE337010T1 (de) 2006-09-15

Family

ID=23111093

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02769298T ATE337010T1 (de) 2001-05-07 2002-04-29 Desinfizierende und solubilisierende steroidzusammensetzungen

Country Status (9)

Country Link
US (1) US20020198174A1 (de)
EP (2) EP1385528B1 (de)
JP (1) JP2004529167A (de)
AT (1) ATE337010T1 (de)
AU (1) AU2002308544B2 (de)
CA (1) CA2446528A1 (de)
DE (1) DE60214157T2 (de)
ES (1) ES2269763T3 (de)
WO (1) WO2002089815A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
JP2002523475A (ja) * 1998-09-02 2002-07-30 アラーガン・セイルズ・インコーポレイテッド 防腐したシクロデキストリン含有組成物
WO2004069280A1 (en) * 2003-02-06 2004-08-19 Cipla Ltd Pharmaceutical inclusion complexes containing a steroid and optionally an antibacterial agent
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
AU2004312096A1 (en) * 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
AU2011235943B2 (en) * 2003-12-31 2014-06-26 Cydex Pharmaceuticals, Inc Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
CN100548271C (zh) 2004-01-20 2009-10-14 阿勒根公司 用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
ATE497787T1 (de) 2004-03-12 2011-02-15 Cipla Ltd Sterilisationsprozess für steroide
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
EP1761283A2 (de) * 2004-06-07 2007-03-14 California Institute Of Technology Biologisch abbaubares polymer-wirkstofffreisetzungssystem
US20060006361A1 (en) * 2004-07-08 2006-01-12 Joseph Callerame Clathrate of chlorine dioxide
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178050A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an increased lung depositon
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197487A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an increased lung deposition
WO2007076448A2 (en) * 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
JP2009526851A (ja) * 2006-02-14 2009-07-23 ワイス ERβ選択的リガンドの水性薬学的配合物
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US20080097335A1 (en) 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
JP2010531898A (ja) * 2007-06-28 2010-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド 鼻および眼へのコルチコステロイド水溶液送達
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
US8054177B2 (en) * 2007-12-04 2011-11-08 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene using patient monitoring
US8545554B2 (en) 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
NZ627781A (en) 2012-01-23 2016-10-28 Sage Therapeutics Inc Neuroactive steroid formulations and methods of treating cns disorders
SG10201608148TA (en) 2012-08-21 2016-11-29 Sage Therapeutics Inc Methods Of Treating Epilepsy Or Status Epilepticus
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドForsight Vision4, Inc. 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
TW202400182A (zh) 2016-03-08 2024-01-01 美商賽吉醫療公司 神經活性類固醇,其組合物及用途
MA46997B1 (fr) 2016-11-29 2022-01-31 Oculis SA Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmique
BR112021026564A2 (pt) 2019-07-01 2022-02-15 Oculis SA Método para estabilizar o ph de uma composição aquosa compreendendo um fármaco

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
DE3612538A1 (de) * 1986-04-14 1987-10-15 Dispersa Ag Stabilisierung von quecksilberhaltigen konservierungsmitteln in augentropfen
US4822819A (en) * 1986-11-07 1989-04-18 Alcon Laboratories, Inc. Use of trimoprostil and derivatives in glaucoma therapy
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5504113A (en) * 1994-03-02 1996-04-02 Allergan, Inc. Enhancement of benzalkonium chloride preservative activity in formulations containing an incompatible drug
US5891913A (en) * 1994-10-10 1999-04-06 Novartis Finance Corporation Ophthalmic and aural compositions containing diclofenac potassium
JP3170619B2 (ja) * 1995-04-20 2001-05-28 参天製薬株式会社 有機アミンを配合したプラノプロフェン点眼液
US5744154A (en) * 1995-09-06 1998-04-28 Laboratoire Chauvin S.A. Ready-to-use indomethacin-based eye lotion
JP3883739B2 (ja) * 1998-05-22 2007-02-21 株式会社メニコン コンタクトレンズ用殺菌液
JP2003517441A (ja) * 1998-09-25 2003-05-27 アルコン ラボラトリーズ, インコーポレイテッド 徐放性で快適な眼疾病用組成物および眼疾病の治療方法

Also Published As

Publication number Publication date
DE60214157D1 (de) 2006-10-05
US20020198174A1 (en) 2002-12-26
EP1702619A2 (de) 2006-09-20
HK1061520A1 (en) 2004-09-24
ES2269763T3 (es) 2007-04-01
WO2002089815A2 (en) 2002-11-14
WO2002089815A3 (en) 2003-02-20
AU2002308544B2 (en) 2006-09-07
EP1385528A2 (de) 2004-02-04
JP2004529167A (ja) 2004-09-24
DE60214157T2 (de) 2007-07-12
CA2446528A1 (en) 2002-11-14
EP1385528B1 (de) 2006-08-23

Similar Documents

Publication Publication Date Title
DE60214157D1 (de) Desinfizierende und solubilisierende steroidzusammensetzungen
ATE459313T1 (de) Medizinische vorrichtungen
ATE531340T1 (de) Ballon-expandierbarer stent und herstellungsverfahren dafür
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
TR200103575T2 (tr) Sülfonamid ve sülfamid ikameli/katkılı imidazokinolinler
DE60320430D1 (de) Medizinische vorrichtungen und herstellungsverfahren dafür
CY1107325T1 (el) Διαδικασια για την επικαλυψη ιατρικων συσκευων χρησιμοποιωντας υπepκρισιμο διοξειδιο του ανθρακα
ID26989A (id) Smilagenin dan anzurogenin-d untuk pengobatan penyakit alzheimer
WO2002061027A8 (en) Nanozeolites for malodor control
DE60331458D1 (de) Kombinationschemotherapie mit chlorotoxin
NL300364I2 (nl) Geïnactiveerd split influenzavirus van influenzastam A/California/7/2009 (H1N1) (X-179A), desgewenst van een pandemische influenzastam in een officieel verklaarde pandemische situatie
ATE410082T1 (de) Desodorisierungszusammensetzung für tabakgeruch, desodorisierungsmittel für tabakgeruch und zigaretten- und tabakpackung mit vermindertem sekundärrauchgeruch
DE60101232D1 (de) Elektronenemittierende Quelle, Baugruppe und Verfahren zu deren Herstellung
CY1108281T1 (el) 17-α-υποκατασταθεισα-11-β-υποκατασταθεισα-4-αρυλ και 21-υποκατασταθεισα 19-νορπρεγναδιενοδιονη ως νεοι αντι-προεμμηνορροϊκοι παραγοντες.
EP1507556A4 (de) Calicheamicin-derivat-trägerkonjugate
NL1027052A1 (nl) Operationele versterker van rail-naar-rail van klasse AB.
ATE472598T1 (de) Cd4+cd25+ regulatorische t-zellen aus menschlichem blut
WO2001026693A3 (en) Manufacture of polyglutamate-therapeutic agent conjugates
ATE353909T1 (de) 3-stickstoff-6,7-dioxygenierte steroid verbindungen und verwendungen davon
MXPA03006933A (es) Aparato y metodo para desorodizar y refrescar el ambiente.
ECSP044997A (es) DERIVADOS SUSTITUIDOS DEL INDENO [1,2-c] ISOQUINOLINA
DE60232660D1 (de) Humane dr4-antikörper und deren anwendungen
WO2004037299A3 (en) Air scenting compositions for spray application on air scenting devices
DE60228184D1 (de) Verfahren zur Herstellung von Chondroitinsulfaten aus K4-Polysaccharid und so hergestellte Produkte
CY1112591T1 (el) Απο του στοματος φαρμακοτεχνικες μορφες της κλαντριβινης

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties